We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Gensight Biologics SA (SIGHT) EUR0.025

Sell:€0.27 Buy:€0.28 Change: €0.0085 (3.16%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:€0.27
Buy:€0.28
Change: €0.0085 (3.16%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:€0.27
Buy:€0.28
Change: €0.0085 (3.16%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Gensight Biologics SA is a France-based biopharmaceutical company. The Company develops and commercializes gene therapy-based treatments of retinal degenerative diseases. It develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The Company intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

Contact details

Address:
74 Rue du Faubourg Saint-Antoine
PARIS
75012
France
Telephone:
+33 (1) 76217220
Website:
https://www.gensight-biologics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SIGHT
ISIN:
FR0013183985
Market cap:
€31.61 million
Shares in issue:
107.44 million
Sector:
Biotechnology
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Laurence Rodriguez
    Chief Executive Officer, Director
  • Philippe Motte
    Deputy Chief Executive Officer, Senior Vice President - Regulatory Affairs and Quality, Chief Pharmacist
  • Jan Umiastowski
    Chief Financial Officer
  • Scott Jeffers
    Chief Technology Officer
  • Magali Taiel
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.